Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21380893 | 0.75 | FFAR1 (0.36) | GPR84 | |
| SCHEMBL3928782 | 0.75 | GPR84 (0.36) | GPR84 | |
| SCHEMBL11370107 | 0.75 | ALDH1A1 (0.38) | GPR84 | |
| SCHEMBL20970972 | 0.72 | HTR2A (0.39) | GPR84 | |
| SCHEMBL3483060 | 0.72 | PBRM1 (0.54) | ATMGPR84 | |
| SCHEMBL9955950 | 0.71 | IMPDH2 (0.40) | — | |
| SCHEMBL1450915 | 0.71 | MEN1 (0.41) | GPR84 | |
| SCHEMBL28570341 | 0.71 | CYP2A6 (0.52) | — | |
| SCHEMBL2300723 | 0.71 | IMPDH2 (0.52) | — | |
| SCHEMBL5818954 | 0.69 | HSD17B10 (0.46) | ATMGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20180258044-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| EP-3344615-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2018-07-11 | — | — | EP | disclosed |
| EP-2734521-B1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| WO-2017037116-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| US-9505755-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
| EP-0164633-A2 | Indole derivatives | MERCK PATENT GmbH (DE) | 1985-12-18 | — | — | EP | disclosed |
| EP-0004532-B1 | 1-ARYLOXY-3-NITRATOALKYLAMINO-2-PROPANOLS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | MERCK PATENT GmbH (DE) | 1981-10-14 | — | — | EP | disclosed |
| US-4288452-A | 1-Aryloxy-3-nitratoalkylamino-2-propanols and use as β-receptor blocker | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-09-08 | — | — | US | disclosed |
| EP-0004532-A1 | 1-Aryloxy-3-nitratoalkylamino-2-propanols, process for their preparation and pharmaceutical compositions | MERCK PATENT GmbH (DE) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | ATM 3772/4885GPR84 71/4885 |
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | ATM 1837/4885GPR84 865/4885 |
| US-20180258044-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | ATM 1837/4885GPR84 865/4885 |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | ATM 1837/4885GPR84 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.